Issue link: http://osercommunicationsgroup.uberflip.com/i/808989
Chain Drugstore Daily Sunday, April 23, 2017 2 8 we've eliminated the time it takes to fla- vor medications altogether. The feedback from early adopters has been phenome- nal. Not only does it make the process of flavoring easier, we're finding that phar- macists and technicians are more inclined to consult with patients because flavoring doesn't interrupt workflow. Another thing I'll highlight, since we're laser focused on making the pro- gram easier to use for pharmacy teams and easier to understand for customers, is our new Flavor Focus initiative. In the past year, as we've pored through reams of dispensing and usage data, its become clear to us that there are seven medications that make up a clear major- ity of flavoring opportunities in phar- macy. In time for back-to-school sea- son, we'll be rolling out new customer- facing and pharmacy-only tools to help the taste choice decision go quickly and smoothly at the counter or drive-thru, with maximum impact on the customer experience. CDD: Why should chain pharmacy exec- utives care about FLAVORx? SA: What we bring to the table aligns so well with the initiatives many chain pharmacies are focused on right now. It's all about the customer and her expe- rience in the store. Does she feel a con- nection to her pharmacy team? Does she feel cared for? Is her time being respected? Are the service offerings rel- evant to her life? Do they solve a prob- FLAVORx (Cont'd. from p. 1) lem? For mothers (and fathers too), the flavoring service impacts each of these things. We give pharmacists and techni- cians a reason to engage with customers in a way that demonstrates genuine care for her and her family. When her child is sick, nothing matters more to that mother, in that moment, than getting her son or daughter well again. By provid- ing a solution to the common struggle of giving children medicine, and mak- ing medicine-time a less stressful expe- rience, pharmacies that consistently offer the flavoring service, in a fun, engaging way, are leaving a lasting impact with their customers and grow- ing market share. CDD: You mentioned the word "fun." Can you expand on that? SA: We talk a lot about how we bring smiles to people's faces. There's delight in choosing how the medicine will taste and making the medicine-time experi- ence a better one. It's a unique offering, and in many cases, unexpected. After 100 million scripts flavored we recog- nize that pharmacy teams who excel with the program do so because they have fun with it. They let children use the Flavor Wheel. They hand out our sugar-free lollipops. They make up jin- gles. No joke! We really try to help proj- ect the pharmacy impact into the home experience and the pharmacist gets the credit. For more information, go to www .flavorx.com, call 800.884.5771 x201 or email info@flavorx.com. PAR PHARMACEUTICAL: INNOVATIVE, COST-EFFECTIVE Since 1978, Par Pharmaceutical has been at the forefront of developing, manufacturing, marketing and distrib- uting safe, innovative and cost-effec- tive pharmaceuticals that help improve patient quality of life. Every week in America, several million Par prescrip- tions are dispensed. In return for the trust that is placed in the company, it is committed to providing products of uncompromising quality. In fulfilling this mission, it delivers value to its customers and the physicians and patients that rely on it. In September 2015, Endo International PLC acquired Par Pharmaceutical, merging the business with Qualitest, thereby expanding the generics business to a top industry leader. Endo develops, manufactures, markets and distributes quality brand- ed pharmaceutical and generic prod- ucts through its operating companies. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. Today, Par Pharmaceutical's sales place it among the top four largest generic pharmaceutical companies in the United States. Par conducts manu- facturing in the United States and abroad, and markets and/or licenses more than 250 prescription drug prod- uct families. At Par, its most important resource is the talent and dedication of its more than 2,800 professionals in offices in Chestnut Ridge, New York; Irvine, California; Rochester, Michigan; Stratford, Connecticut; Chennai, India; Montebello, New York; London, England; and Huntsville Alabama. Each employee is part of a culture that values integrity, customer focus, team- work, innovation and performance. Since the beginning of 2015, Par has acquired Ethics Bio Lab Pvt Ltd, an India-based contract research organization that conducts bioavail- ability, bioequivalence, pharmacoki- netic and clinical endpoint studies, and Innoteq, Inc., a developer and manu- facturer of innovative coated products, including orally dissolving thin films and transdermal patches. Par possesses one of the most promising new product pipelines in the generic drug industry, with more than 116 products awaiting FDA approval, including almost 35 first to files, and more than 100 other products in d e v e l o p m e n t with continued focus on para- graph 4 and first to file opportunities. In recent years, the company has introduced generic versions of several major pharmaceuti- cal products, including the following; Diclofenac Sodium Topical Gel 1% (Endo's Voltaren Gel ® ) Fluoxetine HCL Tablets 10mg and 20mg (Lilly's Prozac ® ), Quetiapine Fumarate ER Tablets 50mg,150mg, 200mg and 300mg (AstraZeneca's Seroquel XR ® ), Ezetimibe Tablets 10mg (Merck's Zetia ® ) and Dexmethylphenidate ER Capsules 25mg and 35mg (Novartis' Focalin XR ® ). Visit Par Pharmaceutical at booth #202. For more information, go to www.parpharm.com. insights along the way. Mars Chocolate and Wrigley looked at confectionery shoppers in all dimen- sions, in ways that really revealed their attitudes and behaviors. It shifted the pre- vailing thinking and created new oppor- tunities for category-centric solutions. Qualitative, human stories were married with rigorous big data. The companies gained a deep quantitative understanding across all channels and candy types. More than 30 retailers were included in the study – after all, no solution is truly one size fits all. The outcome? Real, living insights from American confectionery shoppers across the country. A multi-faceted pic- ture of all the attitudes and behaviors that define what people truly love, cope with and even dislike about the confectionery category today. Insight into category drivers and barriers, at checkout and in the aisle. What did Mars Chocolate and Wrigley learn? That shoppers rate the confectionery category nearly 100 per- cent more difficult to shop than other comparable categories, and that 62 per- cent of them make their purchase deci- sion at shelf. Add this to the fact that Mars (Cont'd. from p. 1) shoppers spend nearly all of their 60 sec- onds in the aisle searching instead of shopping, and you end up with a tremen- dous opportunity to capitalize on shopper insights to create category-driving solu- tions. But those insights are only as power- ful as what you do with them, so the com- panies have unearthed seven shopper- validated, concrete imperatives and cre- ated an action-oriented framework that unlocks the power of confectionery at the point of purchase – online and off. Mars Chocolate and Wrigley are already elevating the shopping experi- ence with key partners in markets nation- wide. They are working with retail part- ners to activate customized solutions based on their Path to Purchase insights and strategies and their business objec- tives. These new, insights-driven experi- ences bridge the gap between peoples' expectations of candy and their experi- ence of shopping for it. The future of con- fectionery is now and Mars Chocolate and Wrigley are ready … are you? For more information, visit booths #336- 338, go to www.mars.com, call 800.631.7630 or contact your Mars Chocolate or Wrigley representative. integrity and value built into each and every Amneal product. "Our company's success is enabled by our sharp focus on growth strategy along with significant invest- ments in R&D and infrastructure," explains Jim Luce, Amneal Executive Vice President, Sales and Marketing. With a laser focus on providing superb quality products across all dosage forms, Amneal's momentum is strong. As one of the top 10 generic manufac- turers in the U.S. by prescription vol- ume, and the fastest-growing global generics company (QuintilesIMS), Amneal maintains powerful R&D, effi- cient production, strategic sourcing and a fine-tuned sales operations/logistics engine to fuel its mission. From the start, Amneal has rein- vested heavily, with a disproportionate percentage of its revenue, in growing and broadening its product portfolio across all dosage forms and numerous therapeutic categories. Simultaneously, it continues to expand and enhance infrastructure in order to comfortably service future growth, thus ensuring the capacity to meet anticipated product approvals. "From the early days of our company, there's been an unrelenting commitment to quality, both measura- bly by FDA criteria and attitudinally Amneal (Cont'd. from p. 1) throughout all areas of our organiza- tion," added Luce. "Since the beginning, we've had 48 inspections without any significant 483s across our 10 FDA-approved facilities. This com- mitment to quality stems from our guiding principle to view the consumer of our products like a family member. Would you give your family anything but the very best? This belief perme- ates throughout our organization, instilling great confidence among our customers and our mutual customer, the patient." One thing is clear: there is no sin- gle aspect of Amneal that drives the company's value. It's the entire team – the scientists, engineers, operations, sales and logistics – that maximizes value for its customers. According to Luce, "We believe by focusing on our customers and patients, and standing by the values of quality and integrity, this path will allow us to continue sustaining our dramatic growth for years to come." Today, more than ever, Amneal is the name you can trust for today's generic pharmaceuticals. Delivering a constant stream of high-quality prod- ucts, Amneal strengthens health, well- ness and better quality of life for peo- ple around the globe. For more information, visit booth #302 or go to www.amneal.com.